Dr. Reddy's Laboratories Limited(RDY)Earnings, Financials & Key RatiosDr. Reddy's Laboratories Limited (RDY) stock price & volume — 10-year historical chart
Investment Thesis • Updated 2026Q4
the 86% year-over-year decline in EPS for 2026Q4 and the collapse of operating margins to 0.6% indicate that the company's core profitability is currently under significant structural pressure.
Dr. Reddy's Laboratories Limited (RDY) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Dr. Reddy's Laboratories Limited (RDY) EPS & revenue vs analyst estimates — last 4 quarters
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 13, 2026 | $0.06vs $0.09-33.3% | —vs $870M |
| Q2 2026 | May 12, 2026 | $0.06vs $0.09-33.3% | $789Mvs $887M-11.0% |
| Q2 2026 | May 11, 2026 | $0.06vs $0.09-33.3% | $786Mvs $887M-11.4% |
| Q1 2026 | Jan 21, 2026 | $0.16vs $0.16+0.0% | $952Mvs $928M+2.6% |
Recent stock market news and headlines for Dr. Reddy's Laboratories Limited (RDY)
HYDERABAD, India--(BUSINESS WIRE)---- $RDY #AmericanDepositaryReceipts--Dr. Reddy's Laboratories Limited announces filing of Annual Report on Form 20-F.
Key metrics vs top competitors for Dr. Reddy's Laboratories Limited (RDY)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $14.63 | $12.18B | 25.80 | 8.58% | 12.76% | 12.7% | 0.6% | |
| $67.79 | $9.26B | 18.52 | 11.05% | 2.72% | 12.87% | — | |
| $11.19 | $1.55B | -1.09 | -2.75% | -43.5% | -50.65% | — | |
| $17.05 | $5.44B | 77.50 | 8.05% | 4.02% | — | — | |
| $33.44 | $38.94B | 27.87 | 4.31% | 9.02% | 20.69% | — | |
| $16.96 | $19.75B | -5.65 | -2.98% | -2.04% | -1.97% | — |
Dr. Reddy's Laboratories Limited (RDY) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Get notified when RDY posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Dr. Reddy's Laboratories Limited (RDY) stock FAQ — growth, dividends, profitability & financials explained
Dr. Reddy's Laboratories Limited (RDY) reported $337.10B in revenue for fiscal year 2026. This represents a 2983% increase from $10.94B in 2001.
Dr. Reddy's Laboratories Limited (RDY) grew revenue by 8.6% over the past year. This is steady growth.
Yes, Dr. Reddy's Laboratories Limited (RDY) is profitable, generating $42.88B in net income for fiscal year 2026 (12.8% net margin).
Yes, Dr. Reddy's Laboratories Limited (RDY) pays a dividend with a yield of 0.60%. This makes it attractive for income-focused investors.
Dr. Reddy's Laboratories Limited (RDY) has a return on equity (ROE) of 12.7%. This is reasonable for most industries.
Dr. Reddy's Laboratories Limited (RDY) generated $24.26B in free cash flow for fiscal year 2026. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.
